
|Articles|February 15, 2003
In Brief
Precautionary measure
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
3
Beyond The Walls: The “how and why” behind what drives today’s ophthalmologists
4
Optigo Biotherapeutics names Andreas Wallnöfer, PhD, MBA, to board as lead retinal program advances
5


















































.png)


